Haemonetics (NYSE: HAE) reported Q2 EPS of $0.83, $0.15 better than the analyst estimate of $0.68. Revenue for the quarter came in at $297.48 million versus the consensus estimate of $270.46 million.

For earnings history and earnings-related data on Haemonetics (HAE) click here.